135 related articles for article (PubMed ID: 12845481)
1. T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome.
Michallet AS; Lesca G; Radford-Weiss I; Delarue R; Varet B; Buzyn A
Ann Hematol; 2003 Aug; 82(8):515-517. PubMed ID: 12845481
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H; Ho AD; Thaler J; Stryckmans P; Sonneveld P; de Witte T; Lechner K; Lauria F; Bödewadt-Radzun S; Suciu S
J Natl Cancer Inst; 1993 Apr; 85(8):658-62. PubMed ID: 8468724
[TBL] [Abstract][Full Text] [Related]
3. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
4. Nijmegen breakage syndrome.
van der Burgt I; Chrzanowska KH; Smeets D; Weemaes C
J Med Genet; 1996 Feb; 33(2):153-6. PubMed ID: 8929954
[TBL] [Abstract][Full Text] [Related]
5. Nijmegen breakage syndrome in 13% of age-matched Czech children with primary microcephaly.
Seeman P; Gebertová K; Paderová K; Sperling K; Seemanová E
Pediatr Neurol; 2004 Mar; 30(3):195-200. PubMed ID: 15033202
[TBL] [Abstract][Full Text] [Related]
6. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype.
Sugimoto T; Imoto S; Matsuo Y; Kojima K; Yasukawa M; Murayama T; Kohfuku J; Mizuno I; Yakushijin K; Sada A; Nishimura R; Koizumi T
Ann Hematol; 2001 Dec; 80(12):749-51. PubMed ID: 11797117
[TBL] [Abstract][Full Text] [Related]
8. Nijmegen breakage syndrome (NBS).
Chrzanowska KH; Gregorek H; Dembowska-Bagińska B; Kalina MA; Digweed M
Orphanet J Rare Dis; 2012 Feb; 7():13. PubMed ID: 22373003
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin].
Nagai T; Izumi T; Noborio K; Takatoku M; Ohtsuki T; Machii T; Komatsu N; Ozawa K
Rinsho Ketsueki; 2002 Jul; 43(7):583-5. PubMed ID: 12229130
[TBL] [Abstract][Full Text] [Related]
10. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
[TBL] [Abstract][Full Text] [Related]
11. Seropositive polyarthritis and skin manifestations in T-prolymphocytic leukemia/Sezary cell leukemia variant.
Dybjer A; Hellquist L; Johansson B; Rydgren L; Billström R
Leuk Lymphoma; 2000 Apr; 37(3-4):437-40. PubMed ID: 10752996
[TBL] [Abstract][Full Text] [Related]
12. Deoxycoformycin in the treatment of mature T-cell leukaemias.
Dearden C; Matutes E; Catovsky D
Br J Cancer; 1991 Nov; 64(5):903-6. PubMed ID: 1931613
[TBL] [Abstract][Full Text] [Related]
13. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
14. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
15. T-cell Prolymphocytic Leukemia.
Matutes E
Cancer Control; 1998 Jan; 5(1):19-24. PubMed ID: 10761013
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy with pentostatin in prolymphocytic leukemia.
Pagano L; Ortu-La Barbera EO; Voso MT; Zollino M; Laurenti L; Marra R; Leone G
Haematologica; 1994; 79(6):542-5. PubMed ID: 7896214
[TBL] [Abstract][Full Text] [Related]
17. A new chromosomal instability disorder: the Nijmegen breakage syndrome.
Weemaes CM; Hustinx TW; Scheres JM; van Munster PJ; Bakkeren JA; Taalman RD
Acta Paediatr Scand; 1981 Jul; 70(4):557-64. PubMed ID: 7315300
[TBL] [Abstract][Full Text] [Related]
18. A brief intensive chemotherapy in T-prolymphocytic leukemia.
Billio A; Pescosta N; Rosanelli C; Fabris P; Coser P
Haematologica; 2000 Apr; 85(4):438-9. PubMed ID: 10756378
[No Abstract] [Full Text] [Related]
19. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
Mercieca J; Matutes E; Dearden C; MacLennan K; Catovsky D
J Clin Oncol; 1994 Dec; 12(12):2588-93. PubMed ID: 7989933
[TBL] [Abstract][Full Text] [Related]
20. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
